Eli Lilly Meets Estimates as Revenue Climbs 9%

NEW YORK ( TheStreet) -- Drugmaker Eli Lilly ( LLY) posted third-quarter adjusted earnings of $1.25 million, or $1.13 a share, in line with analysts' estimates.

Reported net income in the quarter was $1.11 a share vs. $1.18 a share a year ago.

Revenue for the third quarter was better than expected, up 9% to $6.15 billion from $5.65 billion in a year ago. A consensus of analysts anticipated revenue of $6.06 billion.

The maker of Cymbalta and Cialis also sharpened earnings guidance for the full year to a range of $3.89 to $3.94 a share from previous guidance of $3.85 to $3.95 a share. The company pointed to health care reform measures and expiring patent on Zyprexa as important drags on growth. Offsetting these will be increasing sales of Alimta, Cialis, Cymbalta, Effient, Humalog and animal health products.

Follow TheStreet on Twitter and become a fan on Facebook.

Global sales of Zyprexa fell 3% to $1.18 billion, while sales of Cymbalta rose 29% to $1.07 billion.

-- Written by Carlton Wilkinson.

If you liked this article you might like

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Here's How Eli Lilly Stock Can Regain Its Footing

Here's How Eli Lilly Stock Can Regain Its Footing

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls